Quotes are not comparable until the material is clearly specified as lavender flower oil, dry extract, or flower powder.

Plant part. For oil: flowering tops / the botanical part named on the oil specification. For extract or powder: specify the exact plant part stated on the raw-material specification—do not assume one plant-part definition covers every lavender material.

For L. angustifolia flower oil, use the applicable current pharmacopoeial or ISO specification for the destination market (commonly Ph. Eur. Lavandulae aetheroleum and/or ISO lavender-oil specifications). Specify GC-FID for quantitation and GC-MS for identity support. Evaluate a multi-constituent profile—including camphor, 1,8-cineole, and lavandulol / lavandulyl acetate—rather than relying on linalool and linalyl acetate alone. ISO 8902 is associated with lavandin Grosso oil; it should not be used as the specification for L. angustifolia flower oil.

Reference GC profile for L. angustifolia flower oil

Reference ranges vary by the applicable pharmacopoeial or ISO specification, origin category and destination market. Final purchase-order specifications should be agreed against the current applicable standard. The figures below are screening discussion ranges for comparing COAs—not a KS catalog grade.

These values are screening references only; they should not be copied into a purchase order without confirming the applicable current monograph, origin category and test method.

Do not copy oil chromatogram percentages onto flower powder or a dry extract unless a volatile-oil or named-marker method is on the specification. Dry-extract pathways: standard extracts.

Treat it as a proprietary preparation rather than a generic lavender-oil specification. We can manufacture generic L. angustifolia oil softgels against an agreed GC specification; proprietary naming requires the appropriate authorization.

A bulk-oil COA does not automatically substantiate the finished softgel label claim. The same principle applies to dry extract: an incoming extract COA does not automatically substantiate a finished capsule claim.

Release path: Incoming identity → ingestible-path or dry-extract assays → fill → delayed-release integrity if claimed → pack → finished tests as scoped → batch COA. Methods: quality control.

Key softgel risks: oxidation, volatile loss, fill–shell compatibility, seam integrity, odor transfer, and delayed-release coating performance.

Origin can affect cost and supply continuity, but it does not replace species, plant part, process or GC specification. Steam distillation is the default L01 identity path; CO₂ extraction is a separate specification when named on the BOM; dry extraction is L02.

Common packaging options include amber/opaque HDPE or PET with induction sealing, or higher-barrier blister formats. Final pack selection should follow the finished-product stability assessment.

Example commercial development range:

40–80 mg lavender oil per softgel, depending on formula architecture and target market.

80 mg/unit is one commonly encountered development brief—not a universal specification or recommended intake.

Write oil milligrams and total fill separately.

OEM. Send your BOM, label or existing specification. We confirm the material route and manufacturing requirements before quoting.
ODM. Send your target market, formula concept, format and target serving size.

Example RFQ.

Lavandula angustifolia oral flower oil [___]mg per softgel, total fill [___]mg,

steam distilled,

delayed-release [yes/no],

ingestible path—or flower extract

[___] mg hard capsule with DER or marker named; destination [US/EU/…];

first order quantity.

Shelf language is a manufacturing brief. Destination-market counsel approves finished copy. FDA structure/function claims are not disease claims and not FDA approval of the bottle.

Keep claim language short: relaxation / calm / evening routine after destination review. Disease or mental-health terminology such as “anxiety” requires destination-market claim review before artwork approval. EU botanical health claims for L. angustifolia on the Article 13.1 list remain on hold; EMA assessment is a herbal medicinal-product file—not a Supplement Facts template.

Oral oil softgels may show oil burp-back; delayed-release is a formulation option when that is a concern. Companion ingredients affect warning language. Topical or aromatherapy case reports are not used here as an oral finished-product specification.

What are “lavender essential oil capsules”?
For B2B supplement briefs, “lavender essential oil capsules” commonly refers to an ingestible lavender oil softgel. “Lavender capsules” may refer to dry extract or flower powder, so the material should be specified before quoting.

Is aromatherapy lavender oil the same material used in oral softgels?
No. A fragrance GC proves odor. An oral lot still needs ingestible-path safety data.

Can you make a Silexan-type or Lavela-type product?
We manufacture generic oral angustifolia oil softgels against an agreed specification. Those trademarks print only with your license.

Steam distilled or CO₂?
Default oral-oil identity is steam-distilled flower oil. CO₂ extract requires a separate raw-material specification and should not be quoted as equivalent to steam-distilled flower oil. Dry extract is the L02 path.

Does origin change the quote?
It can change cost and supply. It does not replace species + GC.

Can a flower-powder COA list linalool 36%?
Only if a volatile-oil assay is actually performed. Otherwise specify flower milligrams.

Do we need enteric coating, or delayed-release?
Most oil briefs that say “enteric” mean no burp-back. Delayed-release is a common option for oil softgels when burp-back is a formulation concern. True pH-enteric is a different coat—name which one.

Can vegetarian lavender-oil softgels be made from HPMC?
HPMC is commonly used for two-piece hard capsules. Vegetarian softgels typically use starch/carrageenan or other non-gelatin shell systems, depending on the softgel technology.